MedXCell Science

MedXCell Science is a France-based regenerative medicine and cell therapy company within the MedXCell group, focused primarily on developing cellular therapies for osteoarthritis. The company was founded in 2018 in Montpellier and is closely linked to the University Hospital of Montpellier and the Institute for Regenerative Medicine and Biotherapy. Its lead program is ADIPOA, an autologous adipose-derived mesenchymal stromal cell therapy for knee osteoarthritis that has been studied in Phase 2 development. MedXCell Science appears to function as the Montpellier operating subsidiary for MedXCell’s regenerative medicine activities rather than as a broad standalone multi-asset biotech with a large disclosed pipeline. The company remains active as a legal entity in France.